Key facts
- It has raised $15.7M; the latest was Later Stage VC in Aug 2025.
- Notable investors include Lapam Capital, Shenzhen Yifeng Investment Management Enterprise, Zero2IPO Venture Capital, Kaitai Capital.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Pleryon Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Pleryon Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Pleryon Therapeutics
Manufacturer of polymer-based biopharmaceutical technologies aims to address unmet clinical needs through innovation in drug delivery and therapeutic solutions. The company's offerings feature advanced polymer platforms designed for precision regulation of drug release and efficacy, serving pharmaceutical partners and healthcare providers, helping them enhance treatment performance and broaden therapeutic possibilities.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2016
- Website
- pleryon.com/
- Ownership
- Privately Held (backing)
Pleryon Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Pleryon Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Pleryon Therapeutics in its N-PORT filings yet. We sweep new filings monthly.